Back to top
more

Sandoz Group AG Sponsored ADR (SDZNY)

(Delayed Data from OTC)

$55.91 USD

55.91
11,882

-0.87 (-1.52%)

Updated Aug 6, 2025 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (83 out of 246)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris

by Zacks Equity Research

SDZNY, TEVA, and VTRS show resilience with strong biosimilar pipelines and margin strategies amid industry headwinds.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats

by Sundeep Ganoria

Sandoz, Teva and Viatris are navigating generic drug pricing pressure with scale, complex generics and cost cuts.

Zacks Equity Research

SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

SDZNY vs. STVN: Which Stock Is the Better Value Option?

Zacks Equity Research

Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals

by Zacks Equity Research

Dr. Reddy's, Sandoz and Teva Pharmaceuticals have been highlighted in this Industry Outlook article.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes

by Sundeep Ganoria

Despite the impact of dynamic shifts in the regulatory landscape for the Zacks Medical - Generic Drugs industry, new product launches should provide some respite to RDY, SDZNY and TEVA.

Zacks Equity Research

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

by Zacks Equity Research

JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.

Zacks Equity Research

ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

by Zacks Equity Research

Intra-Cellular stock gains 15% as it settles Caplyta patent litigation with Sandoz protecting the drug's exclusivity in the United States till July 1, 2040.

Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

Sandoz Group AG Sponsored ADR (SDZNY) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Sandoz Group AG Sponsored ADR (SDZNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Here's Why Sandoz Group AG Sponsored ADR (SDZNY) Is a Great 'Buy the Bottom' Stock Now

by Zacks Equity Research

Sandoz Group AG Sponsored ADR (SDZNY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

SDZNY vs. ZTS: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

SDZNY or ZTS: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SDZNY vs. ZTS: Which Stock Is the Better Value Option?

Zacks Equity Research

SDZNY vs. STVN: Which Stock Is the Better Value Option?

by Zacks Equity Research

SDZNY vs. STVN: Which Stock Is the Better Value Option?

Zacks Equity Research

AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs

by Zacks Equity Research

AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.

Zacks Equity Research

AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View

by Zacks Equity Research

AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.